Abstract
O-039 Consortium for dural arteriovenous fistula outcomes research (CONDOR): endovascular treatment of tentorial dural arteriovenous fistulae
Journal of neurointerventional surgery, Vol.17(Suppl 1), pp.A33-A34
07/01/2025
DOI: 10.1136/jnis-2025-SNIS.39
Abstract
IntroductionTentorial dAVFs (TDAVFs) represent 15% of intracranial dAVFs and are distinct for aggressive presentation; over 95% of TDAVFs present with either hemorrhage or progressive non-hemorrhagic neurological deficits (NHND). Existing literature on endovascular treatment of TDAVF is limited due to both TDAVF rarity and the relatively recent advances in endovascular management. This study from the CONsortium for DAVF Outcomes Research (CONDOR) presents the largest available registry on TDAVFs treated with endovascular techniques.MethodsThe CONDOR consortium compiles data on dAVFs from 16 international centers. Patients between 1990 and 2024 were included for retrospective analysis. Embolization success was defined as angiographically confirmed complete obliteration of the fistula or discontinuation of cortical venous drainage (CVD) in high grade TDAVFs and decreased venous filling in low grade TDAVFs (TDAVFs without CVD).ResultsFrom CONDOR, 122 TDAVFs were selected for endovascular treatment (70% male; mean 56 ± 1.3 years). Eighty percent presented with aggressive symptoms: 50% (61/122) with hemorrhage attributable to the dAVF, 29% (35/122) with NHND related to the dAVF. At the time of diagnosis, 91% of patients were functionally independent. Ninety-seven percent had high Borden grade characterized by the presence of CVD. The median time from diagnosis to embolization was 1 day (IQR 0–26 days). Appropriate vessels could not be selected in 2% (3/122). Primary embolization with liquid agents (e.g., Onyx, PHIL) was most common, followed by liquid agents plus coils. Successful embolization was achieved in 66% (78/119) following all embolization sessions: complete obliteration was achieved in 59% (70/119); and CVD discontinuation or decreased venous filling in patients without CVD was achieved in 7% (8/119). Six percent (7/119) of patients developed permanent neurologic deficits. Following complete TDAVF obliteration, 8% (10/119) of fistulas recurred. The median time to recurrence was 7 months (IQR 5months-1year). On follow-up, 4% (4/119) of patients experienced a new hemorrhage. New NHND occurred in 7% (7/119).ConclusionEndovascular treatment is technically feasible for the majority of TDAVFs. In appropriately selected patients, the rate of treatment success is high, with low risks of peri-procedural complications, fistula recurrence, and new aggressive events.DisclosuresH. Hallak: None. N. Chalouhi: None. B. Gross: None. J. Satomi: None. J. Van Dijk: None. D. Bulters: None. M. Hayakawa: None. G. Lanzino: None. M. Levitt: None. A. Alaraj: None. J. Sheehan: None. J. Osbun: None. G. Zipfel: None. A. Chatterjee: None.
Details
- Title: Subtitle
- O-039 Consortium for dural arteriovenous fistula outcomes research (CONDOR): endovascular treatment of tentorial dural arteriovenous fistulae
- Creators
- H Hallak - Washington University in St. LouisN Chalouhi - University of FloridaB Gross - University of Pittsburgh Medical CenterJ Satomi - Tokushima UniversityJ Van Dijk - University of GroningenD Bulters - University Hospital Southampton NHS Foundation TrustM Hayakawa - University of IowaG Lanzino - Mayo Clinic in ArizonaM Levitt - University of WashingtonA Alaraj - University of Illinois Urbana-ChampaignJ Sheehan - University of VirginiaJ Osbun - Washington University in St. LouisG Zipfel - Washington University in St. LouisA Chatterjee - Washington University in St. Louis
- Resource Type
- Abstract
- Publication Details
- Journal of neurointerventional surgery, Vol.17(Suppl 1), pp.A33-A34
- DOI
- 10.1136/jnis-2025-SNIS.39
- ISSN
- 1759-8478
- eISSN
- 1759-8486
- Publisher
- BMJ Publishing Group LTD
- Language
- English
- Date published
- 07/01/2025
- Academic Unit
- Neurology; Radiology
- Record Identifier
- 9984845654302771
Metrics
1 Record Views